EL7.AI
StocksMedium•13 October 2026•
4 min read

Scienture Preliminary Revenue Rises 256% to About $1.22 Million in Third Quarter

Key Facts

1Scienture's preliminary unaudited revenue reached about $1.22 million in the third quarter.
2Revenue rose 256% quarter on quarter from about $344,000 in the second quarter.
3Arbli unit sales to wholesalers increased 74% quarter on quarter.
4Net loss for the second quarter of 2026 narrowed by about 58% year on year to about $2.8 million.
5The company's shares closed at $3.240 on October 13, 2026, down 17.14%.

Scienture Holdings announced on October 13, 2026, that preliminary unaudited revenue reached about $1.22 million in the third quarter as commercial activity for its pharmaceutical products expanded. The company said in its statement that revenue rose 256% from the second quarter, when it totaled about $344,000. The quarterly increase came from a small revenue base, alongside growth in Arbli unit sales to wholesalers. The quarter also saw the commercial launch of Rezenopy in August 2026, according to Benzinga, bringing a product launched during the revenue reporting period into the company's commercial operations. These developments come as management continues to work toward its goal of achieving profitability in 2027, following continued losses in previous quarterly results.

Detailing Arbli's performance, Scienture said unit sales to wholesalers increased 74% in the third quarter from the second quarter. On access to medical institutions, the company announced that the product had been added to the formularies of 3 U.S. academic centers and hospitals specializing in pediatric care, according to Investing.com. The product's inclusion at these institutions forms part of the commercial expansion that preceded the preliminary revenue announcement for the period. Arbli's liquid formulation was designed for patients who have difficulty swallowing tablets, according to the website's account of the product. Commercial activity for the drug thus includes sales to wholesalers and formulary listings at specialized medical institutions, alongside a liquid formulation intended for this patient group.

Rezenopy is a nasal spray containing naloxone, intended for the emergency treatment of known or suspected opioid overdoses, according to Benzinga. For its commercialization in the United States, Scienture entered into an exclusive sales, marketing and distribution agreement, according to Investing.com. The agreement provides access to about 2,000 opioid treatment program clinics and addiction treatment centers in the U.S. market. The network of institutions covered by the agreement thus includes organizations specializing in treating opioid dependence, alongside centers providing addiction treatment services. The company did not disclose the financial terms of this commercial arrangement, which preceded the revenue announcement and covers sales, marketing and distribution activities for the spray.

Against the financial backdrop to this expansion, results for the second quarter of 2026 showed Scienture continued to incur losses despite improved performance compared with the same period a year earlier. Net loss narrowed by about 58% year on year to about $2.8 million, according to the earnings statement filed with the U.S. Securities and Exchange Commission. The company recorded a gross profit margin of about 97.7% in the same period, according to the statement, while its bottom line remained in the red. The statement of operations in the quarterly report showed an operating loss of $2,699,733 in the second quarter. The previous period's performance thus combined a high gross margin and a year-on-year reduction in net loss with continued losses at both the operating and net levels.

For the stock, the revenue announcement was preceded by a reverse split that Nasdaq designated as effective on October 5, 2026, according to the exchange's notice. The split ratio was 1 share for every 25 shares, according to Scienture's filing with the U.S. Securities and Exchange Commission. The company said the action was intended to "maintain compliance with the minimum bid price requirement under Nasdaq's continued listing standards." In the October 13, 2026, session, the day preliminary revenue was announced, SCNX shares closed at $3.240, down 17.14% on the day, according to historical prices on Investing.com. That session's close came after the reverse split took effect, on a day when the announcement of revenue growth coincided with a decline in the share price over the full session.

On its next financial disclosure, Scienture said full quarterly results would be included in the periodic report it will file with the U.S. Securities and Exchange Commission. This will follow the preliminary unaudited revenue announcement to complete disclosure of third-quarter performance. Further ahead, Benzinga quoted management as targeting profitability in 2027. The wording cited described this as a "goal of achieving profitability in 2027," making it a forward-looking management target. The company places this target date after a phase of commercial expansion that included increased Arbli sales to wholesalers, the launch of Rezenopy and an exclusive agreement providing access to a network of U.S. opioid treatment clinics and addiction treatment centers.

Open on chart